Alto Neuroscience posts corporate presentation outlining precision psychiatry drug pipeline, led by ALTO-207 in treatment-resistant depression
ANRO•Patient data and cash runway
The company expects cash runway through 2030 and said it has dosed more than 500 patients across studies.
Alto also cited a 25 million patient-impact opportunity.
Clinical timeline for pipeline programs
Two registrational Phase 3 TRD trials are planned to start in 2027, with PACE-2 initiation targeted for early 2027.
Pipeline timelines also include:
- ALTO-300 Phase 2b MDD topline data in the first half of 2027
- ALTO-100 Phase 2b bipolar depression topline data in mid-2027
Precision psychiatry strategy and lead program
Alto Neuroscience outlined a precision-psychiatry strategy built on biomarker-driven patient selection to improve efficacy and reduce trial-and-error prescribing.
Lead asset ALTO-207 targets treatment-resistant depression via a fixed-dose pramipexole-ondansetron combination; Phase 2b PACE-1 topline data are expected in the second half of 2027.
